A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia
To evaluate the safety and tolerability of AMG 232. To determine the maximum-tolerated dose (MTD) of AMG 232. To define the pharmacokinetics (PK) of AMG 232 in subjects with relapsed/refractory acute myeloid leukemias (AMLs).
Study Number: 

PH 243913

Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.